Cost-effectiveness of left ventricular-assist devices in end-stage heart failure

Julia Hutchinson, David A Scott, Andrew J Clegg, Emma Loveman, Pamela Lee Royle, Jackie Bryant, Jill L Colquitt

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

With a limited supply of donor hearts, individuals with end-stage heart failure have been offered hope through the use of mechanical devices. Left ventricular-assist devices (LVADs) are a technology designed to work in parallel with the heart but have yet to see widespread use since uncertainty remains as to the cost-effectiveness of this evolving new technology. We have systematically reviewed evidence of cost-effectiveness for LVADs in the bridge-to-transplant and long-term chronic support indications. A total of 18 studies reporting costs were identified. Of these, only four studies reported results in cost-effectiveness terms; two in cost per life-year saved and two in cost per quality-adjusted life-year (QALY). The majority of the other studies were simple cost summations (cost per day or incremental cost) without consideration of efficacy. In the bridge-to-transplant indication, a Danish abstract reported a cost per life-year saved of DKK270k (US$48,000), a UK study reported a cost per QALY of GB pound39,787 (US$78,000) and a Canadian study reported a cost per life-year saved of Can$91,332 (US$86,000). Regarding the long-term chronic support indication, the same Canadian study reported a cost per life-year saved of Can$59,842 (US$56,000), whereas a US study reported a cost per QALY of $36,255-60,057. Assuming a willingness to pay the threshold of GB pound30,000 (US$59,000) per QALY, there is arguably stronger evidence to support the cost-effectiveness of LVAD technology for the long-term chronic support indication. However, the methodological quality of the majority of studies was poor, as was their generalizability, raising concerns over the reliability of these figures. With the limited and declining availability of donor hearts for transplantation, it appears that the future of this technology is in its use as long-term chronic support. Further analyses should be undertaken, particularly alongside randomized, controlled trials and utilizing second- and third-generation devices.
Original languageEnglish
Pages (from-to)175-185
Number of pages11
JournalExpert Review of Cardiovascular Therapy
Volume6
Issue number2
DOIs
Publication statusPublished - Feb 2008

Fingerprint

Heart-Assist Devices
Cost-Benefit Analysis
Heart Failure
Costs and Cost Analysis
Quality-Adjusted Life Years
Technology
Transplants
Equipment and Supplies
Heart Transplantation
Uncertainty
Randomized Controlled Trials

Keywords

  • Cost-Benefit Analysis
  • Health Care Costs
  • Heart Failure
  • Heart Ventricles
  • Heart-Assist Devices
  • Humans

Cite this

Hutchinson, J., Scott, D. A., Clegg, A. J., Loveman, E., Royle, P. L., Bryant, J., & Colquitt, J. L. (2008). Cost-effectiveness of left ventricular-assist devices in end-stage heart failure. Expert Review of Cardiovascular Therapy, 6(2), 175-185. https://doi.org/10.1586/14779072.6.2.175

Cost-effectiveness of left ventricular-assist devices in end-stage heart failure. / Hutchinson, Julia; Scott, David A; Clegg, Andrew J; Loveman, Emma; Royle, Pamela Lee; Bryant, Jackie; Colquitt, Jill L.

In: Expert Review of Cardiovascular Therapy, Vol. 6, No. 2, 02.2008, p. 175-185.

Research output: Contribution to journalArticle

Hutchinson, J, Scott, DA, Clegg, AJ, Loveman, E, Royle, PL, Bryant, J & Colquitt, JL 2008, 'Cost-effectiveness of left ventricular-assist devices in end-stage heart failure', Expert Review of Cardiovascular Therapy, vol. 6, no. 2, pp. 175-185. https://doi.org/10.1586/14779072.6.2.175
Hutchinson, Julia ; Scott, David A ; Clegg, Andrew J ; Loveman, Emma ; Royle, Pamela Lee ; Bryant, Jackie ; Colquitt, Jill L. / Cost-effectiveness of left ventricular-assist devices in end-stage heart failure. In: Expert Review of Cardiovascular Therapy. 2008 ; Vol. 6, No. 2. pp. 175-185.
@article{db0310eef33140a297d71014b017b1e0,
title = "Cost-effectiveness of left ventricular-assist devices in end-stage heart failure",
abstract = "With a limited supply of donor hearts, individuals with end-stage heart failure have been offered hope through the use of mechanical devices. Left ventricular-assist devices (LVADs) are a technology designed to work in parallel with the heart but have yet to see widespread use since uncertainty remains as to the cost-effectiveness of this evolving new technology. We have systematically reviewed evidence of cost-effectiveness for LVADs in the bridge-to-transplant and long-term chronic support indications. A total of 18 studies reporting costs were identified. Of these, only four studies reported results in cost-effectiveness terms; two in cost per life-year saved and two in cost per quality-adjusted life-year (QALY). The majority of the other studies were simple cost summations (cost per day or incremental cost) without consideration of efficacy. In the bridge-to-transplant indication, a Danish abstract reported a cost per life-year saved of DKK270k (US$48,000), a UK study reported a cost per QALY of GB pound39,787 (US$78,000) and a Canadian study reported a cost per life-year saved of Can$91,332 (US$86,000). Regarding the long-term chronic support indication, the same Canadian study reported a cost per life-year saved of Can$59,842 (US$56,000), whereas a US study reported a cost per QALY of $36,255-60,057. Assuming a willingness to pay the threshold of GB pound30,000 (US$59,000) per QALY, there is arguably stronger evidence to support the cost-effectiveness of LVAD technology for the long-term chronic support indication. However, the methodological quality of the majority of studies was poor, as was their generalizability, raising concerns over the reliability of these figures. With the limited and declining availability of donor hearts for transplantation, it appears that the future of this technology is in its use as long-term chronic support. Further analyses should be undertaken, particularly alongside randomized, controlled trials and utilizing second- and third-generation devices.",
keywords = "Cost-Benefit Analysis, Health Care Costs, Heart Failure, Heart Ventricles, Heart-Assist Devices, Humans",
author = "Julia Hutchinson and Scott, {David A} and Clegg, {Andrew J} and Emma Loveman and Royle, {Pamela Lee} and Jackie Bryant and Colquitt, {Jill L}",
year = "2008",
month = "2",
doi = "10.1586/14779072.6.2.175",
language = "English",
volume = "6",
pages = "175--185",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Cost-effectiveness of left ventricular-assist devices in end-stage heart failure

AU - Hutchinson, Julia

AU - Scott, David A

AU - Clegg, Andrew J

AU - Loveman, Emma

AU - Royle, Pamela Lee

AU - Bryant, Jackie

AU - Colquitt, Jill L

PY - 2008/2

Y1 - 2008/2

N2 - With a limited supply of donor hearts, individuals with end-stage heart failure have been offered hope through the use of mechanical devices. Left ventricular-assist devices (LVADs) are a technology designed to work in parallel with the heart but have yet to see widespread use since uncertainty remains as to the cost-effectiveness of this evolving new technology. We have systematically reviewed evidence of cost-effectiveness for LVADs in the bridge-to-transplant and long-term chronic support indications. A total of 18 studies reporting costs were identified. Of these, only four studies reported results in cost-effectiveness terms; two in cost per life-year saved and two in cost per quality-adjusted life-year (QALY). The majority of the other studies were simple cost summations (cost per day or incremental cost) without consideration of efficacy. In the bridge-to-transplant indication, a Danish abstract reported a cost per life-year saved of DKK270k (US$48,000), a UK study reported a cost per QALY of GB pound39,787 (US$78,000) and a Canadian study reported a cost per life-year saved of Can$91,332 (US$86,000). Regarding the long-term chronic support indication, the same Canadian study reported a cost per life-year saved of Can$59,842 (US$56,000), whereas a US study reported a cost per QALY of $36,255-60,057. Assuming a willingness to pay the threshold of GB pound30,000 (US$59,000) per QALY, there is arguably stronger evidence to support the cost-effectiveness of LVAD technology for the long-term chronic support indication. However, the methodological quality of the majority of studies was poor, as was their generalizability, raising concerns over the reliability of these figures. With the limited and declining availability of donor hearts for transplantation, it appears that the future of this technology is in its use as long-term chronic support. Further analyses should be undertaken, particularly alongside randomized, controlled trials and utilizing second- and third-generation devices.

AB - With a limited supply of donor hearts, individuals with end-stage heart failure have been offered hope through the use of mechanical devices. Left ventricular-assist devices (LVADs) are a technology designed to work in parallel with the heart but have yet to see widespread use since uncertainty remains as to the cost-effectiveness of this evolving new technology. We have systematically reviewed evidence of cost-effectiveness for LVADs in the bridge-to-transplant and long-term chronic support indications. A total of 18 studies reporting costs were identified. Of these, only four studies reported results in cost-effectiveness terms; two in cost per life-year saved and two in cost per quality-adjusted life-year (QALY). The majority of the other studies were simple cost summations (cost per day or incremental cost) without consideration of efficacy. In the bridge-to-transplant indication, a Danish abstract reported a cost per life-year saved of DKK270k (US$48,000), a UK study reported a cost per QALY of GB pound39,787 (US$78,000) and a Canadian study reported a cost per life-year saved of Can$91,332 (US$86,000). Regarding the long-term chronic support indication, the same Canadian study reported a cost per life-year saved of Can$59,842 (US$56,000), whereas a US study reported a cost per QALY of $36,255-60,057. Assuming a willingness to pay the threshold of GB pound30,000 (US$59,000) per QALY, there is arguably stronger evidence to support the cost-effectiveness of LVAD technology for the long-term chronic support indication. However, the methodological quality of the majority of studies was poor, as was their generalizability, raising concerns over the reliability of these figures. With the limited and declining availability of donor hearts for transplantation, it appears that the future of this technology is in its use as long-term chronic support. Further analyses should be undertaken, particularly alongside randomized, controlled trials and utilizing second- and third-generation devices.

KW - Cost-Benefit Analysis

KW - Health Care Costs

KW - Heart Failure

KW - Heart Ventricles

KW - Heart-Assist Devices

KW - Humans

U2 - 10.1586/14779072.6.2.175

DO - 10.1586/14779072.6.2.175

M3 - Article

C2 - 18248272

VL - 6

SP - 175

EP - 185

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 2

ER -